Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2022-10-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
September 2022 Quarterly Activities Report & Appendix 4C 8 pages 316.6KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 October 2022, titled 'Avecho Quarterly Activities Report and Appendix 4C'. It contains detailed operational updates, clinical trial progress, business development activities, and a consolidated statement of cash flows for the quarter ended 30 September 2022. The presence of Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document includes substantive financial data and analysis for the quarter, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-10-27 English
Increased CBD absorption in dogs vs commercial comparator 3 pages 78.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 19 September 2022 from Avecho Biotechnology Limited. It reports interim results from pharmacokinetic studies comparing their TPM® CBD formulations to the FDA-approved Epidiolex® product. The content focuses on study highlights, bioavailability data, and market opportunity commentary. There are no financial statements, regulatory certifications, or detailed management discussions typical of annual or interim reports. The document is a corporate announcement of scientific study results and business development updates rather than a formal financial or regulatory filing. It does not fit categories like 10-K, IR, ER, or MDA. It is not a proxy, voting result, or governance document. It is a product and scientific update communicated as a market announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and corporate disclosures that do not fit other specific categories.
2022-09-18 English
Section 708A Cleansing Statement 1 page 93.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 1 September 2022, titled 'Section 708A Cleansing Notice and Appendix 2A'. It discusses the issuance of fully paid ordinary shares following the conversion of options, compliance with the Corporations Act, and mentions that an Appendix 2A relating to the share issue will be released shortly. The content focuses on a share issue and related regulatory notice under Australian law, specifically Section 708A of the Corporations Act, which relates to share issuance without disclosure. There is no detailed financial report or earnings data, nor is it a full annual or interim report. The document is a regulatory announcement about a capital change event (share issuance). According to the filing definitions, announcements regarding new share issues or capital changes fall under 'Share Issue/Capital Change' (SHA). The document length is short and it is an announcement, not a full report, so it is not a 10-K or IR. Therefore, the correct classification is SHA with high confidence.
2022-08-31 English
Application for quotation of securities - AVE 6 pages 27.6KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX (Australian Securities Exchange) for AVECHO BIOTECHNOLOGY LIMITED. It details the issuance and conversion of options into ordinary fully paid shares, the number of securities to be quoted, issue price, and the resulting issued capital. This is a formal announcement related to the company's capital structure changes, specifically the issuance and quotation of new shares following option exercises. It is not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues and related capital changes.
2022-08-31 English
Appendix 4D and Half-year Financial Report 21 pages 616.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Avecho Biotechnology Limited Appendix 4D Half-year report' and references the reporting period ended 30 June 2022, indicating it is a half-year financial report. It contains detailed financial statements including profit or loss, financial position, cash flows, and notes to the consolidated financial statements. It also includes a directors' report and an auditor's review report. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year confirms this is an Interim / Quarterly Report. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2022
2022-08-28 English
June 2022 Quarterly Activities Report & Appendix 4C 8 pages 171.4KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 29 July 2022 titled 'Avecho Quarterly Activities Report and Appendix 4C' for the quarter ended 30 June 2022. It contains detailed operational updates, business development activities, trial progress, and a comprehensive Appendix 4C cash flow report, which is a standard quarterly financial report required by the ASX listing rules. The presence of actual financial data, including cash flow statements and operational highlights for the quarter, indicates this is a substantive interim/quarterly report rather than a brief announcement or a certification. The document length (15,000 characters) and content confirm it is a full quarterly report with financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2022
2022-07-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.